TSE:ATE

Antibe Therapeutics Competitors

C$4.65

-0.23 (-4.71 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

C$4.56

Now: C$4.65▼

C$4.90

50-Day Range

C$4.54

MA: C$5.06▼

C$6.12

52-Week Range

C$3.05

Now: C$4.65▼

C$8.90

Volume298,221 shs

Average Volume232,497 shs

Market CapitalizationC$211.61 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Antibe Therapeutics (TSE:ATE) Vs. APS, BU, TH, BLU, NRI, and PLI

Should you be buying ATE stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Antibe Therapeutics, including Aptose Biosciences (APS), Burcon NutraScience (BU), Theratechnologies (TH), BELLUS Health (BLU), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

Antibe Therapeutics vs. Aptose Biosciences Stock

Antibe Therapeutics (TSE:ATE) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares Antibe Therapeutics and Aptose Biosciences' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.33 million	22.68	C$-35,814,009.00	C($0.79)	-5.91
Aptose Biosciences	N/A	N/A	N/A	C($0.85)	-7.52

Aptose Biosciences has lower revenue, but higher earnings than Antibe Therapeutics. Aptose Biosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Aptose Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	N/A	N/A
Aptose Biosciences	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and Aptose Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	2	0	3.00
Aptose Biosciences	0	0	2	0	3.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 88.68%. Given Aptose Biosciences' higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Antibe Therapeutics.

Summary

Antibe Therapeutics beats Aptose Biosciences on 3 of the 4 factors compared between the two stocks.

Antibe Therapeutics vs. Burcon NutraScience Stock

Antibe Therapeutics (TSE:ATE) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares Antibe Therapeutics and Burcon NutraScience's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.33 million	22.68	C$-35,814,009.00	C($0.79)	-5.91
Burcon NutraScience	C$12,045.00	45,703.54	C$107,101.00	C$0.00	5,140.00

Burcon NutraScience has lower revenue, but higher earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Burcon NutraScience's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	N/A	N/A
Burcon NutraScience	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and Burcon NutraScience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	2	0	3.00
Burcon NutraScience	0	0	1	0	3.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 2.72%. Given Antibe Therapeutics' higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than Burcon NutraScience.

Summary

Burcon NutraScience beats Antibe Therapeutics on 4 of the 7 factors compared between the two stocks.

Antibe Therapeutics vs. Theratechnologies Stock

Antibe Therapeutics (TSE:ATE) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares Antibe Therapeutics and Theratechnologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.33 million	22.68	C$-35,814,009.00	C($0.79)	-5.91
Theratechnologies	C$66.05 million	7.06	C$-34,627,329.00	C($0.37)	-13.47

Theratechnologies has higher revenue and earnings than Antibe Therapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Theratechnologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	N/A	N/A
Theratechnologies	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and Theratechnologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	2	0	3.00
Theratechnologies	0	2	0	0	2.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Theratechnologies has a consensus price target of C$3.75, suggesting a potential downside of 24.55%. Given Antibe Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than Theratechnologies.

Summary

Antibe Therapeutics beats Theratechnologies on 5 of the 8 factors compared between the two stocks.

Antibe Therapeutics vs. BELLUS Health Stock

Antibe Therapeutics (TSE:ATE) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and BELLUS Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	2	0	3.00
BELLUS Health	0	1	2	0	2.67

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Given Antibe Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than BELLUS Health.

Profitability

This table compares Antibe Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	N/A	N/A
BELLUS Health	N/A	N/A	N/A

Valuation & Earnings

This table compares Antibe Therapeutics and BELLUS Health's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.33 million	22.68	C$-35,814,009.00	C($0.79)	-5.91
BELLUS Health	C$15,000.00	29,768.06	C$-42,145,306.00	C($0.54)	-10.59

Antibe Therapeutics has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats BELLUS Health on 5 of the 7 factors compared between the two stocks.

Antibe Therapeutics vs. Nuvo Pharmaceuticals Inc. (NRI.TO) Stock

Antibe Therapeutics (TSE:ATE) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Antibe Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	2	0	3.00
Nuvo Pharmaceuticals Inc. (NRI.TO)	0	0	1	0	3.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Given Antibe Therapeutics' higher possible upside, analysts clearly believe Antibe Therapeutics is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Antibe Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	N/A	N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)	N/A	N/A	N/A

Valuation & Earnings

This table compares Antibe Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO)'s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.33 million	22.68	C$-35,814,009.00	C($0.79)	-5.91
Nuvo Pharmaceuticals Inc. (NRI.TO)	C$76.09 million	5.48	C$-6,980,844.00	C($0.61)	-59.71

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than Antibe Therapeutics. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 4 of the 7 factors compared between the two stocks.

Antibe Therapeutics vs. ProMetic Life Sciences Stock

Antibe Therapeutics (TSE:ATE) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Antibe Therapeutics and ProMetic Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	2	0	3.00
ProMetic Life Sciences	0	0	0	0	N/A

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%.

Profitability

This table compares Antibe Therapeutics and ProMetic Life Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	N/A	N/A
ProMetic Life Sciences	N/A	N/A	N/A

Valuation & Earnings

This table compares Antibe Therapeutics and ProMetic Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.33 million	22.68	C$-35,814,009.00	C($0.79)	-5.91
ProMetic Life Sciences	C$39.91 million	0.00	C$-1,470,117,780.00	C($63.06)	N/A

Antibe Therapeutics has higher earnings, but lower revenue than ProMetic Life Sciences. Antibe Therapeutics is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats ProMetic Life Sciences on 3 of the 5 factors compared between the two stocks.